Synonyms: CK101 | CK‐101 | Example 153 [US20170050936A1] | RX-518 | RX518
Compound class:
Synthetic organic
Comment: Olafertinib (CK‐101) is an orally available third-generation, selective inhibitor of epidermal growth factor receptor (EGFR) harbouring activating mutations (e.g. the resistance mutation T790M, the L858R mutation and the exon 19 deletion (del 19) mutation). It is an irreversible (covalent binding) inhibitor with minimal activity towards the wild type EGFR. The chemical structure is claimed as Example 153 in patent US20170050936A1 [2].
|
|
Classification | |
Compound class | Synthetic organic |
International Nonproprietary Names | |
INN number | INN |
11160 | olafertinib |
Synonyms |
CK101 | CK‐101 | Example 153 [US20170050936A1] | RX-518 | RX518 |
Database Links | |
GtoPdb PubChem SID | 363894157 |
PubChem CID | 117909640 |
Search Google for chemical match using the InChIKey | IDRGFNPZDVBSSE-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | IDRGFNPZDVBSSE |
Search PubMed clinical trials | olafertinib |
Search PubMed titles | olafertinib |
Search PubMed titles/abstracts | olafertinib |
UniChem Compound Search for chemical match using the InChIKey | IDRGFNPZDVBSSE-UHFFFAOYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | IDRGFNPZDVBSSE-UHFFFAOYSA-N |